about
Current and future options in the management and treatment of uterine sarcomaBRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.Role of cytoreductive surgery in recurrent ovarian cancer.Operative and Conservative Treatment of Uterine SarcomasPrognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer.A systematic variant screening in familial cases of congenital heart defects demonstrates the usefulness of molecular genetics in this field.Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC).Prognostic factors for complete debulking in first- and second-line ovarian cancer.Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.Fertility-sparing surgery in ovarian cancer: a systematic review.Surgical intervention in relapsed ovarian cancer is beneficial: pro.Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer.Management of borderline ovarian tumors.Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases.Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer.Outcome of early breast cancer treated in an urban and a rural breast cancer unit in Germany.Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.Response to the letter of Fagotti et al. regarding the manuscript: "Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery".Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?Abdominal wall metastases in patients with ovarian cancer after laparoscopic surgery: incidence, risk factors, and complications.Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer.Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery.Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study.Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer.A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial.Implementation of robot-assisted gynecologic surgery for patients with low and high BMI in a German gynecological cancer center.Synchronous ovarian and endometrial cancer--an international multicenter case-control study.Prognostic Impact of Port-Site Metastasis After Diagnostic Laparoscopy for Epithelial Ovarian Cancer.The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancerStage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic LymphadenectomyUterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety StudyLow-grade Serous Ovarian CarcinomaGenetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer RiskRequirements to assess feasibility of phase 0 trials during major abdominal surgery: variability of PARP activityOutcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer
P50
Q27013559-2DE0781B-F87A-49DA-B994-7D466B996536Q27853316-1DC205DA-0764-4613-94D6-C077C55FD8C7Q30378801-165ED27E-B5B5-4C87-B741-E226BC4BA299Q33626132-38F3A364-FB96-4CB3-B526-C8FF61E946ECQ35905187-6E3AE6BB-5C6B-4806-B4DD-A838BF78BD74Q36474980-F30AA89C-9E85-461F-812E-4C2CDA91B062Q36490507-6AC9CF74-DDE8-4020-A99D-174A4F5D757AQ37643308-6CED331C-7FDF-48FE-B54C-D0ABBDE25B9EQ37656225-9FE7B6CD-E23D-4CF5-9C60-3933AB24F8F8Q38127130-5A1DD339-80C4-49F2-BE3E-AC93B17EBBADQ38165158-ECBFAA42-E196-4EF7-A478-68D3B79EA043Q38424174-A26370F7-341B-486B-8F5D-FF30A37B8298Q38824315-603FE5EF-F7CC-4E32-80BF-2219A322E073Q38967278-03C87D13-F437-4528-ADFB-600556E70AB4Q38985854-2E0B15C0-A9A3-455E-A8AE-675C8D38500EQ39013449-B9EE93AD-2F50-4C67-9BD6-91AF34F959BAQ39365807-DDB3A623-094B-4949-A0CE-6D3830128A43Q40138514-0667ECDC-8631-40E5-AB43-04061E9BAA03Q40184556-E60FCBEC-82A0-41FE-8B6B-94C54B6EE225Q42021066-4660A786-888B-447D-ACFC-F459AB7D2387Q45298388-D00EDE39-875B-4D45-94E3-A03CADEAA3D8Q45337457-9AFE431B-EB69-4859-BACC-8D38A116F257Q45834992-559FC687-E4F7-44EF-B6AA-4BF097582702Q45915702-139F5130-D7D2-4227-B75C-1D3F09334E39Q46121510-3B3779B8-0D1D-4053-951A-08C7A9EE9D72Q47577781-66FB844D-477C-45C0-A523-A35771689EF1Q47804434-E7009199-3FD9-402D-B5ED-E57AE2C5B0AEQ48035213-C09EEE74-F82A-439D-8698-CBC8F46DF63BQ50209197-183DA9B5-02DC-4FA8-A0DA-4224C7D2D85FQ51111361-3B02B23F-9131-4FE3-A9F7-B76923DA557DQ52881564-38667E41-76D8-42B7-A34D-05359DFC9B23Q53067192-CC86F512-D900-451F-A82A-CA1531891911Q53097060-B0F1541F-C115-4211-8582-DA62638A5705Q56958751-476A499E-F69F-4A61-8B46-7759C0C5C536Q57640259-78D89925-801D-40A0-9E7D-AB939B153DDDQ58080907-AA24C3A4-A47B-4AE4-BC7C-4E8617CD040AQ58592773-D0D9FA04-F357-4D39-BF6C-E5926FF33FB0Q62583319-F4F95EB4-79D1-4CCC-8EFE-0B9BCC44DFD1Q83661448-94A111B4-BAA3-4580-87A7-264D414751C8Q83800012-F7D8AAD4-2C55-428E-B0B3-3FE5A859B815
P50
description
investigador
@es
researcher
@en
name
Florian Heitz
@en
type
label
Florian Heitz
@en
prefLabel
Florian Heitz
@en
P31
P496
0000-0002-2412-0352